World Dermatology Market to Record a 7.73% CAGR to 2022, States GBI Research in Its Report Available at MarketPublishers.com09 Jun 2016 • by Natalie Aster
LONDON – Over the last decades, the dermatology marketplace has remained quite saturated for a host of established products. Nevertheless, the clinical and commercial success of biological products in the therapy for psoriasis, along with an increase in the understanding of the disease pathways of a slew of skin conditions, have refreshed interest of pharmacos in the dermatology domain, resulting in turn in the emergence of a cutting-edge pipeline.
Amid the plethora of dermatologic conditions, acne vulgaris, atopic dermatitis and psoriasis have the highest prevalence rates and also the largest pipeline.
Worldwide, the dermatology market value stood at USD 20 billion as of 2015, and it is expected to grow at a remarkable CAGR of 7.73% and amount to the USD 33.7 billion mark by 2022. The market is driven by the adoption of premium biologics that have been approved recently, alongside high-potential late-stage products that will likely be of great value.
In-demand report “Global Dermatology Market to 2022” drawn up by GBI Research gives an all-round, unprejudiced look at the marketplace from a global perspective. The study describes the present-day clinical and commercial landscape for dermatological disorders; examines the structure of the market across each indication, with respect to major molecule types and targets, casting light on the leading commercial assets and market players. It carefully analyses the dermatology pipeline including stratification by development stage, molecular target and molecule type, with a detailed dissection across major indications. The study provides an understanding of the growth in patient epidemiology and revenues for the world dermatology industry, and across the market leaders and key product types. It also assesses the role of premium and generic products in the therapy for the different skin conditions. An insightful analysis of the main trends in co-development and licensing deals is also provided.
More studies by our market research partner are available at GBI Research page.